Evidence map›Paper›PMID 22040840›Full record

Trial reportDiabetes care2012

Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes.

Jody Dushay, Chuanyun Gao, Gosala S Gopalakrishnan, Meghan Crawley, Emilie K Mitten, Elissa Wilker, Janet Mullington, Eleftheria Maratos-Flier

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00456885 (The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus), which is not on this map. Cited by 44 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 7 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00456885 phase4completednot on this map

The Effect of Exenatide on Body Weight, Energy Expenditure and Hunger in Obese Women Without Diabetes Mellitus

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2007 to 2010Enrolled41ConditionsObesity, Impaired Glucose ToleranceArmsexenatide, Placebo
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 7 syntheses or guidelines pooled it, 152 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Jody DushayDepartment of Medicine, Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.jdushay@bidmc.harvard.edu
Chuanyun Gao
Gosala S Gopalakrishnan
Meghan Crawley
Emilie K Mitten
Elissa Wilker
Janet Mullington
Eleftheria Maratos-Flier
Beth Israel Deaconess Medical Center · US

Funding

ZINC STATUS AND T CELL DISORDER IN MILD HUMAN ZINC DEFICIENCYM01RR001032 · BETH ISRAEL DEACONESS MEDICAL CENTER · 1985 to 2005
$23.6M
NCRR NIH HHS M01 RR001032NCRR NIH HHS M01-RR-01032NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1-RR-025758
6 · The paper itself

Abstract

objectiveTo investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. RESEARCH DESIGN AND

methodsForty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period. There was no lifestyle intervention. The primary outcome was change in body weight.

resultsSubjects treated with exenatide lost an average of 2.49 ± 0.66 kg compared with a 0.43 ± 0.63 kg weight gain during placebo treatment. Weight loss with exenatide treatment was noted at 2 weeks. The degree of weight loss could be stratified. A total of 30% of subjects were high responders who lost ≥5% body weight (-7.96 ± 0.52%), 39% were moderate responders who lost <5% body weight (-2.43 ± 0.45%), and 31% were nonresponders who gained weight (1.93 ± 0.53%). Waist circumference also decreased significantly with exenatide treatment. Subjects experienced more nausea during exenatide treatment compared with placebo, but the severity decreased over time and did not correlate with weight loss.

conclusionsShort-term exenatide treatment was associated with modest weight loss and decreased waist circumference in a cohort of obese nondiabetic women. A subset of individuals demonstrated robust weight loss that was detected very early in the course of treatment.

Indexed as

AdultCross-Over StudiesDouble-Blind MethodExenatideFemaleGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsMiddle AgedNauseaObesityPeptidesReceptors, GlucagonVenomsWaist CircumferenceWeight LossExenatideGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorHypoglycemic AgentsPeptidesReceptors, GlucagonVenoms

Identifiers

PMID22040840
PMCPMC3241299
OpenAlexW2070260892

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.